[1] 刘疏影, 陈彪.帕金森病流行现状[J].中国现代神经疾病杂志, 2016, 16(2):98. doi: 10.3969/j.issn.1672-6731.2016.02.007
[2] WANG YQ, TANG BS, YAN XX, et al.A neurophysiological profile in Parkinson's disease with mild cognitive impairment and dementia in China[J].J Clin Neurosci, 2015, 22(6):981. doi: 10.1016/j.jocn.2014.11.030
[3] 刘婷婷, 宋立友, 李宏岩, 等.帕金森病伴认知功能障碍与血尿酸、同型半胱氨酸相关性的研究进展[J].国际老年医学杂志, 2014, 35(6):276. doi: 10.3969/j.issn.1674-7593.2014.06.011
[4] 中华医学会神经病学分会帕金森病及运动障碍学组.中国帕金森病诊断标准(2016版)[J].中华神经科杂志, 2016, 49(4):268. doi: 10.3760/cma.j.issn.1006-7876.2016.04.002
[5] LIEPELT-SCARFONE I, BRANDLE B, YILMAZ R, et al.Progression of prodromal motor and non-motor symptoms in the premotor phase study-2-year follow-up data[J].Eur J Neurol, 2017, 24(11):1369. doi: 10.1111/ene.13397
[6] RAY CK, POEWE W, BROOKS D.Motor and nomotor complications of levodopa:phenomenology, risk factors, and imaging features[J].Mov Disord, 2018, 33(6):909. doi: 10.1002/mds.27386
[7] CHEN W, XU ZM, WANG G, et al.Non-motor symptoms of Parkinson's disease in China:a review of the literature[J].Parkinsonism Relat Disord, 2012, 18(5):446. doi: 10.1016/j.parkreldis.2012.02.002
[8] SHADRINA MI, SLOMINSKY PA, LIMBORSKA SA.Molecular mechanisms of pathogenesis of Parkinson's disease[J].Int Rev Cell Mol Biol, 2010, 281(10):229.
[9] BOSE A, BEAL MF.Mitochondrial dysfunction and oxidative stress in induce pluripotent stem cell models of Parkinson's disease[J].Eur Neurosci, 2019, 49(4):525. doi: 10.1111/ejn.14264
[10] HOOK G, YU J, TONEFF T, et al.Brain pyroglutamate amyloid-β is produced by cathepsin B and is reduced by the eysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic[J].J Alzheimers Dis, 2014, 41(1):129. doi: 10.3233/JAD-131370
[11] DORSZEWSKA J, PRENDECKI M, LIANERI M, et al.Molecular effects of ldopa therapy in Parkinson's disease[J].Curr Genomics, 2014, 15(1):11. doi: 10.2174/1389202914666131210213042
[12] DUTTA G, BARBER DS, ZHANG P, et al.Involvement of dopaminergic neuronal cystatin C in neuronal injury-induced microglial activation and neurotoxicity[J].J Neurochem, 2012, 122(4):752. doi: 10.1111/j.1471-4159.2012.07826.x
[13] 徐金敏, 陈静, 许冉, 等.合并阻塞性睡眠呼吸暂停综合征的帕金森病患者血清胱抑素C水平的变化[J].中华神经科杂志, 2014, 47(6):365. doi: 10.3760/cma.j.issn.1006-7876.2014.06.003
[14] YANG Q, WANG Y, FENG J, et al.Intermittent hypoxia from obstructive sleep apnea may cause neuronal impairment and dysfunction in central nervous system:the potential roles played by microglia[J].Neuropsychiatr Dis Treat, 2013, 9(8):1077.
[15] KITAMURA H, KAMON H, SAWA S, et al.IL-6-STAT3 controls intracellular MHC class Ⅱ alphabeta dimer level through cathepsin S activity in dendritic cells[J].Immunity, 2015, 23(5):491.
[16] 叶明, 陈育华, 刘晓林, 等.帕金森病患者血清半胱氨酸蛋白酶抑制剂C水平的变化及其临床意义[J].中华全科医学, 2016, 14(12):2004.
[17] LEVY E, SASTRE M, KUMAR A, et al.Codeposition of cystatin C with amyloid-beta protein in the brain of Alzheimer disease patients[J].J Neuropathol Exp Neurol, 2001, 60(1):94. doi: 10.1093/jnen/60.1.94
[18] 梁若冰, 雷晶, 张小宁.帕金森病患者合并认知功能障碍与血清Aβ1-42、胱抑素C、尿酸水平的关系[J].神经损伤与功能重建, 2016, 11(2):131.
[19] JESUS S, PEREZ I, CACERES-REDONDO MT, et al.Low serum uric acidconcentration in Parkinson's disease in southern Spain[J].Eur J Neurol, 2013, 20(1):208. doi: 10.1111/j.1468-1331.2012.03745.x
[20] ROZYCK A, JAGODZINSKI PP, KOZUBSKI W, et al.Homocysteine level and mechanisms of injury in Parkinson's diseaseas related to MTHFR, MTR, and MTHFD1 genes polymorphisms and L-Dopa treatment[J].Current genomics, 2013, 14(8):534.
[21] 张丽娜, 屈洪党, 陈育华, 等.血清尿酸水平与帕金森病不同运动亚型之间的关系[J].蚌埠医学院学报, 2017, 42(7):852.
[22] 俱西驰, 屈秋民, 王伟, 等.血清尿酸水平与帕金森病认知功能障碍的关系[J].南京医科大学学报, 2013, 33(1):59.
[23] 黄碧霞, 郭少勇.老年帕金森病患者血清同型半胱氨酸及血尿酸水平与认知功能障碍的相关性分析[J].当代医学, 2019, 25(2):100. doi: 10.3969/j.issn.1009-4393.2019.02.041